Holen Sie sich die Stockscreener-App
3.22
0.92%
-0.03
Handel nachbörslich:
3.22
Immuneering Corp Aktie (IMRX) Neueste Nachrichten
Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates - Stock Titan
Live market analysis of Immuneering CorporationEarnings Overview Summary & Capital Protection Trade Alerts - Newser
Analysts Set Immuneering Corporation (NASDAQ:IMRX) Price Target at $13.25 - Defense World
Volatility clustering patterns for Immuneering CorporationJuly 2025 WrapUp & Weekly Sector Rotation Insights - Newser
Can swing trading help recover from Immuneering Corporation lossesRisk-Managed Swing Setup and Signal Analysis - Newser
Using Python tools to backtest Immuneering Corporation strategiesFree Daily Volume Spike Trading Signals - Newser
Should you hold or exit Immuneering Corporation nowFree Investment Plan With Growth Optimization - Newser
Is Immuneering Corporation showing signs of accumulationFree Trend Analysis for Safer Trades - Newser
Applying chart zones and confluence areas to Immuneering CorporationFree Trade Setups With Clear Risk Limits - Newser
Is Immuneering Corporation stock entering bullish territoryAI Volatility Forecast and Risk Monitor - Newser
Is this a good reentry point in Immuneering CorporationIntraday Movement Recap and Chart Summary - Newser
Quant Tools Rank Immuneering Corporation as High Risk High RewardStep-by-Step Trade Signal Implementation Guide Ready - metal.it
Is it the right time to buy Immuneering Corporation stockExtraordinary earning power - Jammu Links News
What drives Immuneering Corporation stock priceGet high-impact stock recommendations now - Jammu Links News
How many analysts rate Immuneering Corporation as a “Buy”Build a diversified portfolio for maximum returns - Jammu Links News
What are Immuneering Corporation company’s key revenue driversExceptional stock performance - Jammu Links News
Multi asset correlation models including Immuneering CorporationFree Multi-Bagger Potential Stock Forecast Tools - Newser
How does Immuneering Corporation compare to its industry peersStock Strategy Entry Points Backed By Experts - Jammu Links News
Real time breakdown of Immuneering Corporation stock performanceStrong Buy Opportunity with Volume Support - Newser
Immuneering reports Q1 EPS (42c), consensus (58c) - TipRanks
How Efficient Is Immuneering Corporation at Controlling Operating CostsFree Trade Timing Strategy With Technical Data - Newser
Immuneering Corporation’s Price Action Aligns with Quant SignalsConsistent Income Focused Trade List Analyzed - metal.it
Published on: 2025-07-28 06:27:12 - Jammu Links News
What makes Immuneering Corporation stock price move sharplyProven High Yield Signals - metal.it
How strong is Immuneering Corporation company’s balance sheetBreakout profit opportunities - Jammu Links News
What analysts say about Immuneering Corporation stockAccelerated wealth expansion - PrintWeekIndia
Analysts Set Immuneering Corporation (NASDAQ:IMRX) Target Price at $13.25 - Defense World
Is Immuneering Corporation a good long term investmentSuperior stock growth - jammulinksnews.com
Why Immuneering Corporation stock attracts strong analyst attentionShort Term Profit Focus - Newser
Immuneering Corporation Rings the Closing Bell - Nasdaq
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up - Quantisnow
Immuneering's Cancer Drug Patent and FDA Fast Track Status Fuel 151% Upside Potential - AInvest
Revolutionary Cancer Drug Gets Patent Protection Until 2042: Clinical Data Shows 94% Survival vs 67% Standard Care - Stock Titan
Immuneering Corporation shares rise 10.63% intraday after receiving U.S. composition of matter patent for atebimetinib. - AInvest
The MEK effect on cancer — a slow and steady approach to drug resistance - Pharma Voice
Immuneering director Hausman buys IMRX stock worth $19,862 By Investing.com - Investing.com South Africa
Immuneering (IMRX) chief people officer Neufeld buys $2498 in stock By Investing.com - Investing.com South Africa
Immuneering director Hausman buys IMRX stock worth $19,862 - Investing.com
Insider Buying: Thomas Schall Acquires Additional Shares of Immu - GuruFocus
Immuneering (IMRX) Soars 10.66% on Positive Trial Data, Insider Buying - AInvest
At $3.02 Price, Immuneering Corp (IMRX) Is Sitting And Waiting - stocksregister.com
Jefferies raises Immuneering price target to $3.50 from $1.50 on cancer data - Investing.com
Insider Buying: Brett Hall Acquires Additional Shares of Immuneering Corp (IMRX) - GuruFocus
Immuneering (IMRX) CBO Brakewood buys $4804 in shares - Investing.com
Immuneering (IMRX) director Feinberg buys $63k in shares - Investing.com
Immuneering (IMRX) CEO Zeskind buys $50k+ in shares - Investing.com
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients - Pipelinereview
Immuneering (IMRX) Target Price Raised by Mizuho Analyst | IMRX Stock News - GuruFocus
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):